You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Merck
AstraZeneca
McKinsey

Last Updated: December 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Biapenem

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Biapenem?

Biapenem is an investigational drug.

There have been 4 clinical trials for Biapenem. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2017.

The most common disease conditions in clinical trials are Bacterial Infections, Neoplasm Metastasis, and [disabled in preview]. The leading clinical trial sponsors are Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), Haining Health-Coming Biotech Co., Ltd., and [disabled in preview].

There are seven hundred and eighty-one US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Biapenem
TitleSponsorPhase
Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid TumorHaining Health-Coming Biotech Co., Ltd.Phase 2
Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in CombinationRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1
Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult SubjectsRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1

See all Biapenem clinical trials

Clinical Trial Summary for Biapenem

Top disease conditions for Biapenem
Top clinical trial sponsors for Biapenem

See all Biapenem clinical trials

US Patents for Biapenem

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Biapenem   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Biapenem   Start Trial Cyclic boronic acid ester derivatives and methods of making the same Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Biapenem   Start Trial Methods of treating inflammation associated airway diseases and viral infections WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   Start Trial
Biapenem   Start Trial Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same PharmaIN Corporation (Bothell, WA)   Start Trial
Biapenem   Start Trial Inhibitors of metallo-.beta.-lactamase-enzymes McMaster University (Hamilton, CA)   Start Trial
Biapenem   Start Trial Use of gelsolin to treat infections The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
Biapenem   Start Trial Process and intermediates for preparing poly(anhydride-esters) Rutgers, the State University of New Jersey (New Brunswick, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Biapenem

Drugname Country Document Number Estimated Expiration Related US Patent
Biapenem Australia AU2011210567 2030-01-29   Start Trial
Biapenem Canada CA2787784 2030-01-29   Start Trial
Biapenem European Patent Office EP2528893 2030-01-29   Start Trial
Biapenem European Patent Office EP3138838 2030-01-29   Start Trial
Biapenem Japan JP2013518816 2030-01-29   Start Trial
Biapenem Japan JP2016183175 2030-01-29   Start Trial
Biapenem Japan JP5937968 2030-01-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Merck
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.